Thomas, McNerney & Partners

Thomas, McNerney & Partners is a health care venture capital firm with approximately $600 million under management focused on investing in life science and medical technology companies.

The firm targets investments in the pharmaceutical, medical device, biotechnology and diagnostic sectors as well as in other areas utilizing medical technology innovation. Companies developing therapeutic products for life threatening or costly, chronic conditions are of particular interest.

Thomas, McNerney & Partners invests in companies at all stages of their development. In addition to helping entrepreneurs launch companies with seed and early stage funding, the firm provides growth capital to emerging companies to advance clinical development or for product commercialization. The partnership also is involved in spinning out products and divisions from major medical device and pharmaceutical companies, consolidating companies through roll-up strategies and participating in structured financings for public companies as well as recapitalizations.

Thomas, McNerney & Partners, established in 2003 and headquartered in United States, North America., specializes in Early Stage Venture, Late Stage Venture investments across Biotechnology, Health Care, Pharmaceutical, Information Technology, Software, Financial Services, Venture Capital, Finance, CleanTech, Manufacturing. The organization boasts a portfolio of 48 investments, with an average round size of $28.0M and 17 successful exits. Their recent investments include Virdante Pharmaceuticals, OUP (Osage University Partners), Venrock, Biogen, MedImmune Ventures. The highest investment round they participated in was $91.2B. Among their most notable exits are Virdante Pharmaceuticals and OUP (Osage University Partners). Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.